A phase-III trial of doxorubicin and docetaxel versus doxorubicin and paclitaxel in metastatic breast cancer: results of the ERASME 3 study

Cassier, Philippe; Chabaud, Sylvie; Trillet‐Lenoir, Véronique; Peaud, Pierre-Yves; Tigaud, J; Curé, Hervé; Orfeuvre, Hubert; Salles, Bruno César Corrêa; Martin, C.; Jacquin, Jean‐Philippe; Agostini, Cécile; Guastalla, Jean‐Paul; Pérol, David; Bachelot, Thomas

doi:10.1007/s10549-007-9651-3

Cited by 41 publications

(19 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The AT group reported less nausea and vomiting [14]. Some of the published studies showed no differences in either HRQoL or overall survival [5,16,17].…”

Section: Discussionmentioning

confidence: 94%

“…Several studies have been published regarding HRQoL among women treated with first line chemotherapy for metastatic breast cancer [5,[11][12][13]. Two of these studies showed a significantly better response rate and time to progression, but no significant differences in HRQoL were found between the two treatment regimens studied [12,13].…”

Section: Discussionmentioning

confidence: 99%

“…Women with metastatic disease have a relatively short expected survival time. Thus, the impact on health related quality of life (HRQoL) is an important factor to consider when making decisions about treatment at this stage of disease [1][2][3][4][5].…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Quality of life in women with metastatic breast cancer during 9 months after randomization in the TEX trial (epirubicin and paclitaxel w/o capecitabine)

Svensson

Einbeigi

Johansson

et al. 2010

Breast Cancer Res Treat

View full text Add to dashboard Cite

show abstract

“…The AT group reported less nausea and vomiting [14]. Some of the published studies showed no differences in either HRQoL or overall survival [5,16,17].…”

Section: Discussionmentioning

confidence: 94%

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Quality of life in women with metastatic breast cancer during 9 months after randomization in the TEX trial (epirubicin and paclitaxel w/o capecitabine)

Svensson

Einbeigi

Johansson

et al. 2010

Breast Cancer Res Treat

View full text Add to dashboard Cite

show abstract

“…[1][2][3] Both anthracyclines-taxanes combinations yield similar results in terms of the overall survival(OS) and progression-free survival (PFS) in metastatic breast cancer. [4,5] Nevertheless, they are likely to have different toxicity profiles, such as peripheral neuropathy, neutropenia, neutropenic fever, etc. The current evaluation was carried out to evaluate retrospectively the incidence and severity of certain toxicities and dose reduction, delay, G-CSF use of two taxanes (docetaxel, paclitaxel) in clinical practice at a single institution multidisciplinary breast center.…”

Section: Introductionmentioning

confidence: 99%

Toxicities, dose reduction and delay of docetaxel and paclitaxel chemotherapy in breast cancer without distant metastases

et al. 2011

View full text Add to dashboard Cite

The patients in the ACP group experienced more frequent peripheral neuropathy (P=0.025), nausea (P=0.033) than those in the TAC group. Febrile neutropenia was significant in TAC (P=0.001). Increasing age was associated with an increased risk of anemia (P=0.004), fatigue (P=0.009) and pain (P=0.003), and a decreasing body mass index was associated with an increased risk of febrile neutropenia (P=0.009). Dose reduction and delay occurred due to febrile neutropenia and an increase in aspartate aminotransferase (AST)/alanine aminotransferase (ALT). The dose reduction was only significant in the TAC group (P= 0.001). A taxane-based regimen should be chosen for breast cancer patients based on the pharmacokinetics, dosing schedule, clinical activity and toxicity profile that best meet the patient's therapeutic needs and quality of life.

show abstract

“…One phase iii trial that compared docetaxel/doxorubicin with paclitaxel/doxorubicin has been published18. Outcomes were not significantly different in terms of median os (22.6 months vs. 24.1 months) and response (40% vs. 42%).…”

Section: Discussionmentioning

confidence: 94%

Optimal Use of Taxanes in Metastatic Breast Cancer

King¹,

Lupichuk

Baig

et al. 2009

Current Oncology

View full text Add to dashboard Cite

(pharm)* mortality in women 1 . Approximately 6% of women with breast cancer are metastatic at diagnosis 2 , a rate that will account for just over 1300 new breast cancer diagnoses in Canadian women in 2007 1,2 .Unfortunately, many women with early breast cancer will be diagnosed with a metastatic relapse in the years following treatment with locoregional and systemic adjuvant therapies. The goals of treatment in metastatic breast cancer include prolongation of survival, symptom control, and maintenance of quality of life. In Alberta, chemotherapy for breast cancer is prescribed at tertiary, associate, and community cancer clinics, all of which are affiliated with the Alberta Cancer Board.The literature on taxanes and breast cancer has been growing exponentially since the mid-1990s. In the absence of an evidence-based provincial guideline, regional variability in taxane prescription is to be expected. The objective of creating a provincial guideline on the optimal use of taxanes in the management of metastatic breast cancer is to promote evidence-based consistency in practice and hence equitable patient access to appropriate therapies. Guidelines for taxane use in the management of metastatic breast cancer have previously been published. The guidelines published here were developed by the Alberta Cancer Board Provincial Breast Tumour Group Guideline Panel by systematically adapting the recommendations of others and by creating de novo recommendations to account for recent evidence. APPROACH TO GUIDELINE DEVELOPMENT ObjectiveThe objective was to determine the optimal clinical use of taxanes in the management of metastatic breast cancer. Key Clinical QuestionsWhich taxane regimens can be offered to an-• thracycline-naïve patients with metastatic breast ABSTRACTThe role of taxanes in the treatment of breast cancer is becoming increasingly important. In clinical practice, the taxanes are now standard therapy in both early-stage and metastatic breast cancer. Since the 1990s, multiple randomized clinical trials have been evaluating the efficacy of taxanes in the treatment of metastatic breast cancer. These trials have included treatment with taxanes alone or in combination with other chemotherapeutic agents. Pre-existing published guidelines for the use of taxanes in the management of metastatic breast cancer are available. The mandate of the Alberta Cancer Board Provincial Breast Tumour Group Guideline Panel was to consider and adapt the recommendations of the existing guidelines and to develop de novo guidelines to account for current evidence. For this task, the panel used the adapte process, which is a systematic process of guideline adaptation developed by the adapte Collaboration. The recommendations formulated by the panel included the identification of taxane regimens that could be offered in anthracycline-naïve patients, anthracycline-pretreated or -resistant patients, and patients overexpressing the human epidermal growth factor receptor 2. Potential toxicities and benefits in terms of time to progression, p...

show abstract

A phase-III trial of doxorubicin and docetaxel versus doxorubicin and paclitaxel in metastatic breast cancer: results of the ERASME 3 study

Abstract: In this study, paclitaxel or docetaxel combined with doxorubicin were not significantly different in terms of QoL scores and efficacy, but had different toxicity profiles.

Cited by 41 publications

References 22 publications

Quality of life in women with metastatic breast cancer during 9 months after randomization in the TEX trial (epirubicin and paclitaxel w/o capecitabine)

Quality of life in women with metastatic breast cancer during 9 months after randomization in the TEX trial (epirubicin and paclitaxel w/o capecitabine)

Toxicities, dose reduction and delay of docetaxel and paclitaxel chemotherapy in breast cancer without distant metastases

Optimal Use of Taxanes in Metastatic Breast Cancer

Contact Info

Product

Resources

About